No connection

Search Results

JNJ vs RIGL

JNJ
Johnson & Johnson
NEUTRAL
Price
$237.96
Market Cap
$573.46B
Sector
Healthcare
AI Confidence
85%
RIGL
Rigel Pharmaceuticals, Inc.
BULLISH
Price
$32.43
Market Cap
$599.3M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
JNJ
21.55
RIGL
1.66
Forward P/E
JNJ
18.9
RIGL
6.76
P/B Ratio
JNJ
7.03
RIGL
1.52
P/S Ratio
JNJ
6.09
RIGL
2.04
EV/EBITDA
JNJ
17.81
RIGL
3.89

Profitability

Gross Margin
JNJ
68.08%
RIGL
82.02%
Operating Margin
JNJ
23.97%
RIGL
33.19%
Profit Margin
JNJ
28.46%
RIGL
124.72%
ROE
JNJ
35.03%
RIGL
185.94%
ROA
JNJ
8.68%
RIGL
23.15%

Growth

Revenue Growth
JNJ
9.1%
RIGL
21.2%
Earnings Growth
JNJ
48.6%
RIGL
1598.7%

Financial Health

Debt/Equity
JNJ
0.6
RIGL
0.14
Current Ratio
JNJ
1.03
RIGL
2.42
Quick Ratio
JNJ
0.69
RIGL
2.08

Dividends

Dividend Yield
JNJ
2.19%
RIGL
--
Payout Ratio
JNJ
46.6%
RIGL
0.0%

AI Verdict

JNJ NEUTRAL

JNJ presents a dichotomy between strong profitability and deteriorating fundamental health, evidenced by a weak Piotroski F-Score of 3/9. While the company maintains an impressive ROE of 35.03% and a consistent history of earnings beats, the current price of $237.96 trades at a significant premium to its Graham Number of $91.72. Growth remains robust on a YoY basis, but bearish insider sentiment and a very weak technical trend (10/100) suggest immediate headwinds. The stock is fundamentally sound in terms of earnings power but shows signs of operational inefficiency or declining quality in its deterministic health metrics.

Strengths
Exceptional Return on Equity (ROE) of 35.03%
Strong profit margins (28.46%) and gross margins (68.08%)
Consistent earnings beat track record over 25 quarters
Risks
Weak Piotroski F-Score (3/9) indicating declining fundamental health
Bearish insider activity with $58.35M in net sales and zero buys
Low liquidity indicated by a Quick Ratio of 0.69
RIGL BULLISH

RIGL exhibits strong fundamental health with a Piotroski F-Score of 7/9 and a very conservative debt profile (Debt/Equity 0.14). The company is severely undervalued, trading at $32.43, which is significantly below both its Graham Number ($96.8) and its growth-based intrinsic value ($574.66). While technical trends and insider sentiment are currently bearish, the explosive earnings growth (1598.7% YoY) and a P/E ratio of 1.66 suggest a massive valuation gap. The transition from historical losses to consistent earnings beats indicates a successful pivot to profitability.

Strengths
Extreme undervaluation with a P/E of 1.66 and Price/Book of 1.52
Strong financial health indicated by a Piotroski F-Score of 7/9
Explosive earnings growth (1598.7% YoY) and consistent earnings beats
Risks
Bearish technical trend (0/100) suggesting short-term price pressure
Negative insider sentiment with recent selling activity
Potential for non-recurring gains inflating the reported profit margin (124.72%)

Compare Another Pair

JNJ vs RIGL: Head-to-Head Comparison

This page compares Johnson & Johnson (JNJ) and Rigel Pharmaceuticals, Inc. (RIGL) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile